Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dhruv Thakar

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cell Stem Cell|January 5, 2024
Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer riskJason J Northey, Mary-Kate Hayward, Yoshihiro Yui, et al.
Cancer Cell International|September 19, 2022
Intratumoral delivery of TransCon<sup>™</sup> TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine inductionLuis Alejandro Zúñiga, Torben Leßmann, Karan Uppal, et al.
Journal for Immunotherapy of Cancer|July 11, 2022
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancerDavid B Rosen, Anne Månsson Kvarnhammar, Burkhardt Laufer, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cell Stem Cell|January 5, 2024
Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer riskJason J Northey, Mary-Kate Hayward, Yoshihiro Yui, et al.
Cancer Cell International|September 19, 2022
Intratumoral delivery of TransCon<sup>™</sup> TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine inductionLuis Alejandro Zúñiga, Torben Leßmann, Karan Uppal, et al.
Journal for Immunotherapy of Cancer|July 11, 2022
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancerDavid B Rosen, Anne Månsson Kvarnhammar, Burkhardt Laufer, et al.
Pageof 2